Clinical trials: Cholangiocarcinoma Cancer
Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, gallbladder cancer, and pancreatic cancer.
- Trial name
- NCT02646514
- Testing
- Radiofrequency ablation with stenting, stenting
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Hepatocarcinoma, Cholangiocarcinoma
Study on the Quality of Life (QoL) After Liver Surgery
Liver cancer in adult men is the fifth most frequently diagnosed cancer worldwide, and is the second leading cause of cancer-related death in the world.
- Conditions
- Hepatocarcinoma, Cholangiocarcinoma, Quality of Life
- Trial name
- NCT05464706
- Testing
- Synchrolevels
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Humanitas Clinical and Research Center
Cancer of Pancreas, Cancer of Duodenum
Enteral Nutrition After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is the treatment of choice for resectable periampullary cancer. PD is still associated with a relatively a high incidence of delayed gastric emptying.
- Conditions
- Cancer of Pancreas, Cancer of Duodenum, Ampulla of Vater Cancer, Cholangiocarcinoma
- Trial name
- NCT03150615
- Testing
- Early enteral nutrition, Saline, nasojejunal tube insertion
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing Medical University
Biliary Tract Cancer, Cholangiocarcinoma
SHR-1210 in Combination With GEMOX in Patients With Advanced BTC
This is a single-arm, open-label and exploratory clinical study of PD-1 monoclonal antibody SHR-1210 combined with GEMOX regimen (gemcitabine combined oxaliplatin) in the treatment of advanced biliary malignancies.
- Trial name
- NCT03486678
- Testing
- SHR-1210+GEMOX
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer, Pancreas Cancer
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
This prospective, randomized, open-label and multicenter phase III study is aimed to estimate the survival benefit of Early Palliative Care (EPC) combined with standard oncology care including first-line chemotherapy…
- Conditions
- Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer
- Trial name
- EPIC-1511 (NCT02853474)
- Testing
- Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
- Where
- 20 sites in France
- Volunteers
- 480 people
- Sponsor
- Centre Oscar Lambret
Biliary Tract Neoplasms, Pancreatic Neoplasms
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
- Trial name
- NCT07160283
- Testing
- Bile duct cancer cohort, Pancreatic cancer cohort
- Volunteers
- 96 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Cholangiocarcinoma
Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
This is a clinical trial investigating the effectiveness and safety of the study drug RAD001 in patients with advanced (metastatic) cholangiocarcinoma. Palliative chemotherapy provides some benefit to this group of patients.
- Trial name
- RADiChol (NCT00973713)
- Testing
- RAD001
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- Austin Health
Klatskin Tumor
Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction
In Bismuth II-IV hilar cholangiocarcinoma patients with a predicted survival of longer than 3 months, metallic stent performance is superior to plastic stenting for palliation with respect to outcomes and cost-effectiveness.
- Trial name
- NCT02166970
- Testing
- Metallic stent deployment in hilar obstruction
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Soon Chun Hyang University
Colorectal Cancer, Liver Neoplasms
HAI Via Interventionally Implanted Port Catheter Systems
Procedures to provide interventional implantation of a port catheter system into the hepatic artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open, single-arm trial in patients with…
- Conditions
- Colorectal Cancer, Liver Neoplasms, Hepatocellular Carcinoma, Gallbladder Cancer
- Trial name
- NCT00356161
- Testing
- interventionally implanted hepatic arterial port catheter
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT04164069
- Testing
- Bevacizumab, Dasatinib, Fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Anne Noonan
Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma
Improving a Bile Duct Drainage Procedure in Patients With Inoperable Cancer Blocking the Bile Ducts: Comparing Two Types of Endoscopically Placed Internal Stents to Prevent Blockage of a Lumen Apposing Metal Stent
This study looks at the best way to treat bile duct blockage in people with advanced cancer that cannot be removed by surgery. A blocked bile duct can cause serious symptoms like yellowing of the skin (jaundice), infection, and…
- Conditions
- Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma, Inoperable Malignant Biliary Obstruction, Lumen Apposing Metal Stents
- Trial name
- Opti-LAMS (NCT07115420)
- Testing
- Fully covered self expanding metal stent (FCSEMS) within LAMS, Double pigtail stent (DPS) within LAMS
- Where
- New Zealand
- Volunteers
- 100 people
- Sponsor
- Waikato Hospital
Cholangiocarcinoma
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
Biliary tract cancer (BTC) accounts for 4% of the malignant tumors of the digestive system, and the incidence has increased significantly in recent years.
- Trial name
- NCT04866836
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma
PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.
This is a single-center, single-arm, prospective phase II clinical study to evaluate the effectiveness and safety of Sintilimab combined with capecitabine in patients after radical resection of cholangiocarcinoma.
- Trial name
- SCRCA (NCT05207735)
- Testing
- Sintilimab
- Volunteers
- 73 people
- Sponsor
- Henan Cancer Hospital
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Bile Duct Cancer
Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative.
- Trial name
- NCT05706974
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
HER2 Gene Mutation
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
The study aims to evaluate the efficacy and safety of IAH0968 in combination with gemcitabine and cisplatin for the treatment of HER2-positive unresectable advanced/metastatic malignant tumors and cholangiocarcinoma.
- Trial name
- NCT05991518
- Testing
- Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder…
- Conditions
- Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7
- Trial name
- NCT02392637
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.